Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3191-3201

  Van Meurs, Hannah S ^a   Tajik, Parvin ^a   Hof, Michel H P ^a   Vergote, Ignace ^b   Kenter, Gemma G ^a   Mol, Ben Willem J ^a   Buist, Marrije R ^a   Bossuyt, Patrick M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Additive interaction; Chemotherapy; Ovarian cancer; Surgery; Treatment selection

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RESEARCH; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EXPLORATORY RESEARCH; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ADDITIVE INTERACTION; CHEMOTHERAPY; OVARIAN CANCER; SURGERY; TREATMENT SELECTION;

AGED; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 84884902788     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.013     Document Type: Article

References (33)

1. C.H. Holschneider, and J.S. Berek Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 2000 3 10
2. A. du Bois, M. Quinn, and T. Thigpen 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
3. I. Vergote, C.G. Trope, and F. Amant Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
4. D.S. Chi, R.E. Bristow, and D.K. Armstrong Is the easier way ever the better way? J Clin Oncol 29 2011 4073 4075
5. I. Vergote, A. du Bois, and F. Amant Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol 128 2013 6 11
6. G.A. Omura, M.F. Brady, and H.D. Homesley Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138 1150
7. T. Thigpen, M.F. Brady, and G.A. Omura Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience Cancer 71 1993 606 614
8. D.S. Chi, J.B. Liao, and L.F. Leon Identification of prognostic factors in advanced epithelial ovarian carcinoma Gynecol Oncol 82 2001 532 537
9. J. Warwick, S. Kehoe, and H. Earl Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials Br J Cancer 72 1995 1513 1517
10. S. Marsoni, V. Torri, and M.G. Valsecchi Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)) Br J Cancer 62 1990 444 450
11. W.J. Hoskins, B.N. Bundy, and J.T. Thigpen The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166
12. A.P. Makar, M. Baekelandt, and C.G. Trope The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer Gynecol Oncol 56 1995 175 180
13. B.C. Cooper, A.K. Sood, and C.S. Davis Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer Obstet Gynecol 100 2002 59 64
14. D. Parker, C. Bradley, and S.M. Bogle Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer Br J Obstet Gynaecol 101 1994 888 893
15. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
16. M. Bonetti, and R.D. Gelber A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 2000 2595 2609
17. M. Bonetti, and R.D. Gelber Patterns of treatment effects in subsets of patients in clinical trials Biostatistics 5 2004 465 481
18. A.A. Lazar, B.F. Cole, and M. Bonetti Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot J Clin Oncol 28 2010 4539 4544
19. X. Song, and M.S. Pepe Evaluating markers for selecting a patient's treatment Biometrics 60 2004 874 883
20. X. Song, and X.H. Zhou Evaluating markers for treatment selection based on survival time Stat Med 30 2011 2251 2264
21. P.M. Rothwell Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 2005 176 186
22. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00075712 (accessed 2nd November 2012).
23. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00715286 (accessed 2nd November 2012).
24. T. Onda, K. Matsumoto, and T. Shibata Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602 Jpn J Clin Oncol 38 2008 74 77
25. A. du Bois, A. Reuss, and E. Pujade-Lauraine Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
26. J. Morrison, K. Haldar, and S. Kehoe Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Cochrane Database Syst Rev. 8 2012 CD005343
27. I. Vergote, C.G. Trope, and F. Amant Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer J Clin Oncol 29 2011 4076 4078
28. F.G. Lawton, C.W. Redman, and D.M. Luesley Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer Obstet Gynecol 73 1989 61 65
29. I. Vergote, I. De Wever, and W. Tjalma Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
30. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076
31. S. Tangjitgamol, S. Manusirivithaya, and M. Laopaiboon Interval debulking surgery for advanced epithelial ovarian cancer Cochrane Database Syst Rev 10 2010 CD006014
32. R.E. Bristow, E.L. Eisenhauer, and A. Santillan Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2007 480 490
33. M.J. Rutten, K.N. Gaarenstroom, and T. Van Gorp Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study BMC Cancer 12 2012 31